Alessandro Marino
We examined anti-RBD, micro neutralization assay, and IFN- production in 216 PLWH on ART with advanced disease receiving the third dose of an mRNA vaccine after a median of 142 days from the second dose in order to investigate the safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH). At least one adverse effect, usually a minor one, is seen in 68% of PLWH. Particularly when a heterologous combination with mRNA-1273 is used as the third shot, the humoral response after the third dose was strong and higher than that attained with the second. Cell-mediated immunity, however, does not change. Our findings suggest the third dose's utility for PLWH who are currently undergoing suppressive ART and who have significant immune dysregulation.